- Hyphens Pharma (SGX:1J5), established in 1998, is Singapore’s leading specialty pharmaceutical and consumer healthcare group with a diverse footprint in ASEAN countries.
- Hyphens Pharma holds exclusive licenses and main distributorship with top pharmaceutical companies globally, mainly from Europe and the United States. They also build a strong franchise by means of in-licensing and R&D collaborations with reputable research institutions in Singapore.
- - Read this at SGinvestors.io -
- - Read this at SGinvestors.io -
- Hyphens Pharma products are selling in the premium market while Novem are targeting mostly the public sector. Prior to Novem acquisition, ~42% of sales are from the government. With the Healthier SG scheme, the public sector will grow at a faster pace, benefitting the Hyphens Pharma from the acquisition where ~60% of Novem sales are to government hospitals and polyclinics.
Hyphens Pharma – Investment Thesis
Internationalization
- Read more at SGinvestors.io.
Yeo Peng Joon SAC Capital Research | Matthias Chan SAC Capital | https://www.saccapital.com.sg/ 2023-05-25
Read also SAC's most recent report:
2024-03-26 Hyphens Pharma International - What A Difference A Half Makes.
Previous report by SAC:
2023-11-20 Hyphens Pharma International - 3Q23 Business Update.
Price targets by 2 other brokers at Hyphens Pharma Target Prices.
Listing of research reports at Hyphens Pharma Analyst Reports.
Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividends & Corporate Actions,
Hyphens Pharma News Articles
